Implantable drug-loaded device

An implantable, drug-loaded technology, applied in medical science, prosthesis, surgery, etc., can solve problems such as overactive effect, necrosis, tissue ulceration, etc.

Active Publication Date: 2021-08-03
BIOTYX MEDICAL (SHENZHEN) CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, if excessive zinc is released during zinc corrosion, it will kill smooth muscle cells, even endothelial cells and other normal tissue cells, and eventually lead to tissue ulceration or necrosis at the implant site
[0004] When the implantable drug-loaded device can release both zinc and drugs that inhibit the proliferation of vascular tissue, the zinc and the drug will work together on the vascular tissue, and synergistically produce the effect of inhibiting angiogenesis and intimal hyperplasia. It is easy to act too strong and produce toxicity, leading to adverse tissue reactions and even tissue necrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Implantable drug-loaded device
  • Implantable drug-loaded device
  • Implantable drug-loaded device

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] 34.6mm in surface area 2 The surface of the iron alloy vascular stent body is uniformly galvanized by electroplating to form a zinc coating on the surface of the iron alloy vascular stent body, and then the mixture of rapamycin and polylactic acid is uniformly sprayed on the surface of the zinc coating, and after drying, it is coated on the zinc coating A rapamycin-polylactic acid coating was formed on the surface to obtain the vascular stent of this embodiment. In this embodiment, the zinc coating is the zinc-containing part, and the ferroalloy stent body and the zinc coating form a zinc-containing matrix.

[0075] Through the aforementioned detection method, the content ρ of rapamycin in the zinc-containing matrix per unit area was measured to be 1.4 μg mm -2 The zinc content p corroded per unit time in the zinc-containing substrate per unit area in 8.3vol.% superior pure acetic acid aqueous solution at 25 ° C is 0.065 μg mm -2 min -1 , 15p+ρ=2.375.

[0076] The s...

Embodiment 2

[0078] will have a surface area of ​​34.6mm 2 Half of the pure iron vascular stent body along the length direction is immersed in the galvanizing solution, and the electroplating method is used to uniformly galvanize to form a zinc coating on the half surface of the pure iron vascular stent body, and then the galvanized pure iron vascular stent The main body is placed in a vacuum furnace for heat treatment. The furnace cavity pressure is 20 Pa, the heat treatment temperature is 300 ° C, and the heat treatment time is 3 hours. After the mixture of lactic acid is dried, a rapamycin-polylactic acid coating is formed on the surface of the stent body to obtain the vascular stent of this embodiment. In this embodiment, a zinc-iron alloy layer covering the surface of the pure iron vascular stent body is formed after heat treatment, the zinc-iron alloy layer is the zinc-containing part, and the pure iron vascular stent body and the zinc-iron alloy layer form a zinc-containing matrix. ...

Embodiment 3

[0082] 34.6mm in surface area 2 The surface of the iron alloy vascular stent body is uniformly galvanized by electroplating to form a zinc coating on the surface of the iron alloy vascular stent body, and finally the mixture of rapamycin and polylactic acid is evenly sprayed on the surface of the zinc coating, and after drying, it is coated on zinc A rapamycin-polylactic acid coating was formed on the surface of the coating to obtain the vascular stent of this embodiment. In this embodiment, the zinc coating is the zinc-containing part, and the ferroalloy stent body and the zinc coating form a zinc-containing matrix.

[0083] Through the aforementioned detection method, the content ρ of rapamycin in the zinc-containing matrix per unit area was measured to be 0.5 μg mm -2 The zinc content p corroded per unit time of the zinc-containing substrate per unit area in 8.3vol.% superior pure acetic acid aqueous solution at 25 ° C is 0.14 μg mm -2 min -1 , 15p+ρ=2.6.

[0084] The s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
surface areaaaaaaaaaaa
Login to view more

Abstract

The invention relates to an implantable drug-carrying device, which comprises a zinc-containing substrate and an active drug layer attached to the zinc-containing substrate. In the zinc-containing substrate per unit area, the content of the active drug is ρ (μg mm ‑2 ), the zinc content of the zinc-containing substrate per unit area corroded per unit time in 8.3vol.% superior grade pure acetic acid aqueous solution is p (μg·mm ‑2 min ‑1 ), the value of ρ and the value of p satisfy the following relationship: 0.1≤15p+ρ≤3.5; wherein, 0.005≤p≤0.14. The zinc release rate of the implantable drug-loaded device matches the content of the active drug, so that after implantation in the body, the synergistic effect of the zinc and the drug can effectively inhibit the proliferation of smooth muscle cells without killing cells and causing tissue necrosis.

Description

technical field [0001] The invention relates to the field of interventional medical devices, in particular to an implantable drug-carrying device. Background technique [0002] At present, the commonly used treatment methods for lumen stenosis are interventional procedures such as percutaneous transluminal angioplasty, that is, the narrowed lumen is expanded to a normal size by implantable devices. Therefore, local damage will occur at the implantation site. During the critical period of tissue repair, the proliferation of smooth muscle cells is the most serious. When the luminal tissue passes through the critical period of repair, smooth muscle proliferation gradually slows down and finally reaches stability. Therefore, active drugs can be loaded on the surface of the implantable device to effectively inhibit cell proliferation in the lesion, keep the lumen unobstructed, and achieve therapeutic effects, that is, when the implantable drug-loaded device is implanted in the hu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61L31/02A61L31/08A61L31/16
CPCA61L31/022A61L31/088A61L31/08A61L31/16A61L2300/102A61L2300/606A61L31/082A61L31/10A61L31/14A61L2420/08A61L2300/416C08L67/04A61L27/04A61L2300/216A61L2300/236A61L2300/41A61L2300/42A61L2430/30A61L31/148
Inventor 秦莉林文娇刘自强张德元
Owner BIOTYX MEDICAL (SHENZHEN) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap